Company intelligence / Profile preview

PharmaEngine, Inc.

Ownership: Public · 4162
Employees: ~44
Development stage: Commercial

Overview

PharmaEngine has a marketed product ONIVYDE for metastatic pancreatic cancer and a Phase 1 clinical trial candidate PEP07 for hematological tumors and solid tumors.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

6 assets

PEP03

5 more assets in the full pipeline.

Financials

Market cap: $232M
Total revenue: $27.8M
Enterprise value: $78.3M

Beyond the preview

Go deeper on PharmaEngine, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmaEngine, Inc..